Compare Atmos Energy Corporation (ATO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Atmos Energy Corporation trades at $169.57 (market cap $28.59B), while State Street SPDR S&P Biotech ETF trades at $159.77. The key difference: Atmos Energy Corporation pays a 2.36% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atmos Energy Corporation nearer its low. Which is the better fit depends on your goals.
| ATO | XBI | |
|---|---|---|
Market Cap | $28.59B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $192.25 | $164.28 |
52-Week Low | $162.44 | $86.92 |
Enterprise Value | $38.40B | — |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $167.92, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company reported Q3 2026 EPS of $1.43, beating estimates of $1.35, with revenue growth of 4.8% year-over-year. Strong profitability metrics include a 28.5% net income margin and 62.2% gross margin, while valuation ratios show a P/E of 20.2 and P/S of 5.7. Recent corporate developments include board appointments and dividend declarations of $1.00 per share.
ATO presents a mixed outlook with solid fundamentals and analyst support but faces technical headwinds. The consensus price target of $190.57 suggests 13.5% upside potential, supported by 45% buy ratings. Risks include high capital expenditures impacting cash flow and debt levels near $7.9 billion. Earnings growth and rate approvals provide catalysts, though the stock's bearish technical trend warrants caution near-term.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
